Free Australia-wide shipping on orders over $100

News

From One Receptor to Three: How Target Count Tracks With Weight-Loss Results Across Three Trials

From One Receptor to Three: How Target Count Tracks With Weight-Loss Results Across Three Trials

-14.9% Against -2.4%: What STEP 1 Reported in 2021

Semaglutide acts on a single target, the GLP-1 receptor. In the STEP 1 trial, published in 2021, the trial found a mean weight change of -14.9% over 68 weeks, compared with -2.4% on placebo over the same 68 weeks.

That single-receptor result became a reference point for later trials testing drugs built to hit more than one hormone pathway at once.

Semaglutide is a prescription-only medicine in Australia, as most peptides are, and its approved uses are set out in its product information rather than in any single trial result.

Adding a Second Target: SURMOUNT-1 and GIP

Tirzepatide was built to act on two receptors, GLP-1 and GIP, rather than one. In SURMOUNT-1, a 2022 trial, the trial found that its highest dose arm reached a mean weight change of -20.9% over 72 weeks, against -3.1% on placebo.

The trial ran four weeks longer than STEP 1 and enrolled a different participant group, so the gap between -20.9% and -14.9% cannot be read as a clean effect of adding the GIP target alone.

Trial length, baseline body weight, and enrolment criteria all shift mean results, and SURMOUNT-1 differed from STEP 1 on all three counts.

Three Receptors, 48 Weeks: The Retatrutide Phase 2 Numbers

Retatrutide goes further again, acting on GLP-1, GIP and glucagon receptors. In its 2023 phase 2 trial, the trial found that the highest dose arm reached a mean weight change of -24.2% over 48 weeks, against -2.1% on placebo.

This result came from a shorter trial than either STEP 1 or SURMOUNT-1, which matters because weight change in these trials tends to continue accruing over time rather than plateauing early.

A phase 2 trial is also smaller and earlier in the regulatory process than the phase 3 trials behind STEP 1 and SURMOUNT-1, so its numbers carry a different evidentiary weight.

Why Three Numbers in a Row Are Not a Ranking

Lined up, the three placebo-adjusted gaps look like a staircase: one receptor at -14.9%, two receptors at -20.9%, three receptors at -24.2%. But STEP 1, SURMOUNT-1 and the retatrutide phase 2 trial ran for different durations, recruited different participants, and used different trial designs, so the figures sit side by side without being a head-to-head comparison.

The TGA states that approval decisions rest on the full evidence package submitted for a specific product and its specific proposed use, not on cross-trial comparisons of percentages from separate studies.

Readers comparing these numbers should treat trial length and participant selection as variables as important as the number of receptors a molecule engages.

What Changes When a Committee Reviews These Results

When a regulatory committee assesses a new multi-receptor peptide, it weighs the trial design alongside the headline percentage. A committee voted on tirzepatide's approved indications only after reviewing the full SURMOUNT-1 dataset, not the single -20.9% figure in isolation.

The practical lesson is to read trial length and placebo gap together, not the top-line number alone, before drawing conclusions about what a receptor target adds.

Most peptides are prescription-only medicines in Australia. This article reports published research and regulation for general education and is not medical advice. Speak to your doctor.

Sources

  1. Once-Weekly Semaglutide in Adults with Overweight or Obesity (New England Journal of Medicine, 2021)
  2. Tirzepatide Once Weekly for the Treatment of Obesity (New England Journal of Medicine, 2022)
  3. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial (New England Journal of Medicine, 2023)